Origin Life Sciences, Inc. (OLSI)
| Market Cap | 78.97M |
| Revenue (ttm) | n/a |
| Net Income | -8.84M |
| EPS | -0.45 |
| Shares Out | 19.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OLSI
Origin Life Sciences is a clinical-stage biotechnology company that has been developing a proprietary patented high-energy plasma device that generates nitric oxide (“NO”) in the form of a plasma/NO stream and delivers it to targeted locations of the body. The stream can potentially be used for various therapeutic purposes, including as an anti-infective, anti-inflammatory and tissue-regenerative therapy for chronic wounds and skin and soft tissue infections. The U.S. Food and Drug Administration previously determined that our product will be a... [Read more]
Financial Performance
Financial StatementsNews
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies and Devices for Treatment of Battlefield Wounds in Prolonged Care to Prevent Infection
PRINCETON, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Origin Life Sciences, Inc., a clinical-stage biotechnology company developing a proprietary patented high-energy plasma device that generates nitric ...
Medical device developer Origin Life Sciences files and sets terms for a $15 million IPO
Origin Life Sciences, which is developing a high-energy plasma medical device for dermal and wound care, filed on Monday with the SEC to raise up to $15 million in an initial public offering.
Origin Life Sciences IPO Registration Document (S-1)
Origin Life Sciences has filed to go public with an IPO on the NYSE American.